Psychedelics

  • Signed LOI to acquire a compounding pharmacy in Calgary, Alberta, Canada
  • Valuation of approximately 3.5x TTM EBITDA of $180,000
  • Levitee Labs to use compounding capabilities to build its own drug brands

Levitee Labs Inc. (CSE: LVT) (OTCMKTS: LVTTF) (FSE: 7H7) (the "Company" or "Levitee"), an integrative wellness company with a diversified portfolio of healthcare and wellness assets, has signed a letter of intent to acquire 51% of the issued and outstanding shares in a compounding pharmacy in Calgary, Alberta, Canada.

This pharmacy will be used as an initial base for the production and distribution of pharmaceutical products for Levitee Labs, which will include pain and depression management products such as ketamine. Levitee plans to expand operations by introducing a research laboratory for the development and production of various formulations in this space. The current owner and operator of the pharmacy will join Levitee Labs and assist with operations across Levitee's Alberta portfolio, which includes 5 addiction focused clinics, and 3 specialized pharmacies.

As stipulated in the agreement, Levitee will pay $306,000 in cash for 51% of the issued and outstanding shares in the pharmacy, equating to approximately 3.5x TTM EBITDA. This LOI is non-binding and remains subject to the drafting of definitive agreements, approval from Levitee Labs' board, and regulatory body approvals.

"This will be an important acquisition for Levitee Labs as we direct our research and development efforts into psychedelic medicines for depression, addiction and pain management, including ketamine compounding, which will offer our patients various solutions for their chronic comorbidities," commented Fady Hannah-Shmouni, MD FRCPC, Chief Medical and Scientific Officer, and President of Clinics and Pharmacies at Levitee Labs. "Our continued expansion across Western Canada reaffirms our commitment to mental healthcare delivery through the integration of psychedelic medicines and therapies into a medical home care model".

Levitee expects to fund this acquisition using its current cash reserves.

About Levitee Labs
Levitee Labs is establishing itself as a leader in the integrative wellness space. Through leveraging an M&A regimen that focuses on the centralization of complementary integrative wellness assets, Levitee Labs aims to transform mental health and addiction treatments through the integration of psychedelic medicines and therapies into a medical home care model. The company's current portfolio of assets includes: Levitee Clinics and Levitee Pharmacies, which includes a group of five operating addiction and pain treatment clinics in Alberta, Canada; Block MD, the first technology company in Alberta, Canada to receive provincial approval for electronic-prescriptions in the addiction treatment space; three pharmacies operating in Alberta, Canada specialized in filling prescriptions for patients with substance use disorders, mental health conditions, and chronic pain; MONKE Nutraceuticals, a company specialized in developing and distributing premium functional mushroom supplements sold via online portals; and Earth Circle Organics, a direct-to-consumer and wholesaler of supplements and superfood products with 180+ SKUs in its product lineup across three brands. Further information about Levitee Labs is available on its website at leviteelabs.com .

Further information about the Company is available on its website at www.leviteelabs.com .

Forward-Looking Statements

This news release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, which address activities, events, outcomes, results, developments, performance, or achievements that Levitee Labs anticipates or expects may or will occur in the future (in whole or in part) should be considered forward-looking information. Such information may involve, but is not limited to, statements respecting Levitee Labs' business plans and proposed products, and the benefits derived from mushroom-infused products.  Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results "may", "could", "would", "might" or "will" (or other variations of the forgoing) be taken, occur, be achieved, or come to pass. These statements and other forward-looking information are based on assumptions made by Levitee Labs based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release as well as management's current expectations or beliefs regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenditures.  These assumptions may also be based on information obtained from third-party industry analysts and other third-party sources. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Levitee Labs as of the date such statements are made, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to risks associated with the following: Levitee Labs' limited history of operations; ability to secure additional financing; negative cash flow from operating activities since inception; regulatory requirements; changes in consumer preferences; supply of raw materials; reliance on a limited number of products; brand awareness; the ability to develop, market and produce new products; dependence on certain key senior managers; reliance on third parties for manufacturing and packaging; potential product liability claims and product recalls; and significant competition.  For additional information regarding these risks, please see the risk factors identified and reported in Levitee Labs' public filings under its SEDAR profile at www.sedar.com. Any and all forward-looking information contained in this press release is expressly qualified by this cautionary statement.  Readers are cautioned not to place undue reliance on forward-looking statements or information. The forward-looking information is made as of the date of this news release, and Levitee Labs assumes no obligation to publicly update or revise such forward-looking information, except as required by applicable securities laws.  The CSE (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release and accepts no responsibility for the adequacy or accuracy hereof.

The CSE (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.

For further information about Levitee, please contact:
Levitee Media Contact
media@leviteelabs.com
Levitee Investor and Corporate Communications
ir@leviteelabs.com



Primary Logo

News Provided by GlobeNewswire via QuoteMedia

Awakn Life Sciences Announces Signing of Lease for Second Clinic in Norway

Awakn Life Sciences Announces Signing of Lease for Second Clinic in Norway

Trondheim in central Norway will be the location of Awakn's 4th clinic

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today the signing of a 5-year lease to open Awakn Clinics Trondheim. The new clinic is part of the second stage of Awakn's Nordic expansion plans, following on from last week's announcement of a move to a larger premises for its Oslo clinic.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
magic mushrooms

How Do Psychedelics Clinical Trials Work?

A flurry of clinical trials are at play in the psychedelics space as the industry waits for a landmark first approval.

Several publicly traded companies are pursuing the tried-and-true pharmaceutical path when it comes to drug development, drawing on lengthy and significant research in the hopes of eventually bringing their products to market.

To learn more about what steps psychedelics companies have to complete, the Investing News Network (INN) caught up with Dr. Amy Reichelt, director of neuropharmacology at Cybin (NYSEAMERICAN:CYBN,NEO:CYBN), following the recent Wonderland business conference. She outlined the drug development process with a focus on clinical trials.

Keep reading...Show less
Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130

Lobe Sciences Provides an Update to Clinical Development Plans for Its Proprietary Psilocin Product, L-130

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced an update for its clinical development plans for its proprietary Psilocin based compound L-130.

Philip J. Young, Chairman and Chief Executive Officer of the Company stated, "Subsequent to our last communication on the cGMP production of L-130, I wanted to update our stakeholders on our progress as we advance into our Phase 1 clinical trials. We have received regulatory clearance to conduct our Phase 1 study which is a combination of safety and pharmacokinetics evaluation of a fixed dose of L-130." Young continued, "It is important to remember that we are approaching the development of a global commercial markets with a disruptive approach to treating anxiety conditions with sequential sub psychedelic dosing of our compounds. Since the majority of patients with anxiety related conditions are cared for by their personal family physician our goal is to create a treatment regimen that is effective and easily a prescribed by patient's personal physician."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
pink mushrooms under ultraviolet light

What Does the FDA Think About Psychedelics? (Updated 2022)

The development of the growing psychedelics industry depends on myriad factors, but one of the most critical is its relationship with a principal medical authority.

The US Food and Drug Administration (FDA) is the leading body for drug approvals in the US. Its job is to review clinical data from established medical studies on the feasibility of drug compounds or products as treatments for specific ailments.

Essentially, this federal body determines whether medical products will ultimately reach the hands of patients.

Keep reading...Show less

COMPASS Pathways to participate in upcoming Evercore ISI HealthCONx Conference

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the Evercore ISI HealthCONx Conference at 9:15am ET on 30 November 2022.

A live audio webcast of the fireside chat will be accessible from the "Events" page of the Investors section of the COMPASS website. The replay of the webcast will be accessible for 30 days following the event. For more information, please visit ir.compasspathways.com .

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Albert Labs

Albert Labs Announces Private Placement

Albert Labs International Corp. (Albert Labs [CSE: ABRT] [FSE: VB50], the "Company"), a biopharmaceutical drug discovery company focused on gaining regulatory approval for active compounds to treat various mental health conditions, has announced a non-brokered private placement for gross proceeds of up to $3,000,000 (the "Offering"), with the first tranche raised at a price of CAD $0.08 per Unit (the "Units"); intermediate closings may take place as determined by the Company.

Each Unit is comprised of one common share (the "Common Share") and one-half of one whole Common Share purchase warrant (each whole warrant, a "Warrant") with each whole Warrant entitling the holder to purchase one additional Common Share of the Company at a price of CAD $0.12 per Share for a period of 12 months from the date of issuance. In the event that the Company's common shares have a closing price on the CSE of greater than CAD $0.15 per common share for a period of 10 consecutive trading days, the Company may accelerate the expiry date of the Warrants by giving notice to the holders thereof and, in such case, the Warrants will expire on the 30th day after the date on which such notice is given to the holder by the Company.

Keep reading...Show less

Latest Press Releases

Related News

×